The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.
 
Patrick Neven
No Relationships to Disclose
 
Hope S. Rugo
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
Speakers' Bureau - Genomic Health
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Bristol-Myers Squibb; Eisai; Eisai; Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Masakazu Toi
Honoraria - AstraZeneca; Bayer; C & C Research Laboratories; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Pfizer; Sanofi; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Kyowa Hakko Kirin; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Pfizer
Research Funding - AFI technology; Astellas Pharma (Inst); C & C Research Laboratories; Chugai Pharma; Japan Breast Cancer Research Group (Inst); Shimadzu (Inst); Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Genomic Health; Lilly
Other Relationship - Japan Breast Cancer Research Group ; Japan Breast Cancer Research Group ; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Eisai; Genomic Health; Lilly; Novartis
Research Funding - Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen
Honoraria - Eisai; Polyphor; Roche/Genentech
Consulting or Advisory Role - Polyphor; Roche/Genentech
Research Funding - Eisai; Lilly; Novartis; Polyphor; Roche/Genentech
 
Susana Barriga
Employment - Lilly
 
Yong Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
George W. Sledge
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
Honoraria - Symphony Evolution
Consulting or Advisory Role - Coherus Biosciences; Peregrine Pharmaceuticals; Radius Health; Symphony Evolution; Taiho Pharmaceutical
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Radius Health; Taiho Pharmaceutical